{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:56:35Z","timestamp":1792166195499,"version":"4.4.0"},"reference-count":94,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.acuroe.2026.502005","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:09:33Z","timestamp":1783469373000},"page":"502005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations for the prevention and treatment of adverse effects of intravesical BCG"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-8453","authenticated-orcid":false,"given":"J.L.","family":"Alvarez-Ossorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cozar-Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Espinosa-Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Florido-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martinez-Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Olivares-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rodriguez-Quecedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Rodriguez-Faba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2026.502005_bib0010","series-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer","first-page":"77","author":"Gontero","year":"2025"},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol."},{"issue":"10","key":"10.1016\/j.acuroe.2026.502005_bib0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 years of Bacillus Calmette\u2013Gu\u00e9rin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0025","first-page":"480","article-title":"Treatment of high-risk non-muscle invasive bladder cancer with Immuno BGC Moreau RJ. The ENCORE-01 trial","volume":"4","author":"Fernandez-Gomez","year":"2021","journal-title":"Br J Cancer Res."},{"key":"10.1016\/j.acuroe.2026.502005_bib0030","unstructured":"ENCORE-01. Estudio de IMUNO BCG Moreau RJ en Pacientes con C\u00e1ncer de Vejiga No Muscular Invasivo de Alto Riesgo. 2025 [access 24 de septiembre de 2025]. Available from: https:\/\/ensayosclinicos.es\/ensayo\/estudio-de-imuno-bcg-moreau-rj-en-pacientes-con-cancer-de-vejiga-no-muscular-invasivo-de-alto-riesgo\/."},{"issue":"5_suppl","key":"10.1016\/j.acuroe.2026.502005_bib0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1200\/JCO.2025.43.5_suppl.717","article-title":"Global real-world patients characteristics, treatment patterns, and impact of BCG shortage in patients with high-risk non-muscle invasive bladder cancer","volume":"43","author":"Bedke","year":"2025","journal-title":"J Clin Oncol."},{"issue":"10","key":"10.1016\/j.acuroe.2026.502005_bib0040","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.acuro.2024.06.004","article-title":"Documento de consenso sobre las implicaciones de la normalizaci\u00f3n del suministro del Bacillus Calmette-Gu\u00e9rin en el manejo del paciente con tumor vesical no-m\u00fasculo invasivo (TVNMI)","volume":"48","author":"Rodr\u00edguez Faba","year":"2024","journal-title":"Actas Urol Esp."},{"issue":"10","key":"10.1016\/j.acuroe.2026.502005_bib0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol."},{"issue":"23","key":"10.1016\/j.acuroe.2026.502005_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235554","article-title":"Immune predictors of response after Bacillus Calmette-Gu\u00e9rin treatment in non-muscle-invasive bladder cancer","volume":"15","author":"Rodr\u00edguez-Izquierdo","year":"2023","journal-title":"Cancers."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0055","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cells11030357","article-title":"New perspectives in the medical treatment of non-muscle-invasive bladder cancer: immune checkpoint inhibitors and beyond","volume":"11","author":"Audisio","year":"2022","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0060","doi-asserted-by":"crossref","first-page":"70.e1","DOI":"10.1016\/j.urolonc.2024.01.013","article-title":"Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: insights from qualitative interviews and a cross-sectional survey","volume":"42","author":"Kopenhafer","year":"2024","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.acuro.2017.10.003","article-title":"Eficacia y seguridad de distintas cepas de BCG en el tratamiento del tumor vesical en pr\u00e1ctica cl\u00ednica habitual","volume":"42","author":"Unda-Urzaiz","year":"2018","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/curroncol32010018","article-title":"Retrospective, non-interventional, multicenter study on the effectiveness and safety of intravesical Bacillus Calmette-Guerin in patients with non-muscle-invasive bladder cancer: real-world experience from six hospital centers in Greece","volume":"32","author":"Angelopoulos","year":"2024","journal-title":"Curr Oncol."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0075","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2425529","article-title":"Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer","volume":"20","author":"Peng","year":"2024","journal-title":"Hum Vaccin Immunother."},{"issue":"31","key":"10.1016\/j.acuroe.2026.502005_bib0080","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016223","article-title":"The impact of age on intravesical instillation of Bacille Calmette-Guerin treatment in patients with high-grade T1 bladder cancer","volume":"98","author":"Cal\u00f2","year":"2019","journal-title":"Medicine (Baltimore)."},{"issue":"9","key":"10.1016\/j.acuroe.2026.502005_bib0085","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1080\/14740338.2024.2374921","article-title":"Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database","volume":"23","author":"Peng","year":"2024","journal-title":"Expert Opin Drug Saf."},{"issue":"10","key":"10.1016\/j.acuroe.2026.502005_bib0090","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical Bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Gu\u00e9rin treatment","volume":"39","author":"Alanee","year":"2021","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.acuroe.2026.502005_bib0095","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med."},{"issue":"10516","key":"10.1016\/j.acuroe.2026.502005_bib0100","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001941","article-title":"Rapamycin enhances BCG-specific \u03b3\u03b4 T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study","volume":"9","author":"Ji","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","article-title":"Sequential combination of mitomycin C plus bacillus Calmette-Gu\u00e9rin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol."},{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0115","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4111\/icu.20210340","article-title":"Low-dose versus standard-dose bacille Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer: systematic review and meta-analysis of randomized controlled trials","volume":"63","author":"Choi","year":"2022","journal-title":"Investig Clin Urol."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CAD.0000000000000456","article-title":"Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer","volume":"28","author":"Nouhaud","year":"2017","journal-title":"Anticancer Drugs."},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0125","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2026.502005_bib0130","article-title":"BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies","volume":"17","author":"Bourlotos","year":"2023","journal-title":"Front Neurosci."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12894-025-01734-6","article-title":"Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Gu\u00e9rin) therapy: a retrospective observational study","volume":"25","author":"Aksakalli","year":"2025","journal-title":"BMC Urol."},{"issue":"Suppl 1","key":"10.1016\/j.acuroe.2026.502005_bib0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000052381","article-title":"BCG intravesical instillations: recommendations for side-effects management","volume":"37","author":"Rischmann","year":"2000","journal-title":"Eur Urol."},{"issue":"10","key":"10.1016\/j.acuroe.2026.502005_bib0145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuroe.2026.502005_bib0150","series-title":"Instituto Nacional de Seguridad e Higiene en el Trabajo. Ministerio de Empleo y Seguridad Social.Medicamentos peligrosos","year":"2016"},{"key":"10.1016\/j.acuroe.2026.502005_bib0155","series-title":"Vejicur. Ficha t\u00e9cnica","first-page":"1","year":"2025"},{"issue":"6","key":"10.1016\/j.acuroe.2026.502005_bib0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.acuro.2018.03.001","article-title":"Revisi\u00f3n de la evidencia sobre el manejo de medicamentos y productos peligrosos en los servicios de Urolog\u00eda. Documento de consenso entre la Asociaci\u00f3n Espa\u00f1ola de Urolog\u00eda y la Sociedad Espa\u00f1ola de Farmacia Hospitalaria","volume":"42","author":"Unda-Urzaiz","year":"2018","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ijun.12311","article-title":"Adaptation of a side-effect questionnaire for identifying symptoms caused by bacillus Calmette-Guerin intravesical therapy","volume":"16","author":"Goncalves Semedo","year":"2022","journal-title":"Int J Urol Nurs."},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0170","first-page":"604","article-title":"Suivi de la tol\u00e9rance de la BCG th\u00e9rapie endov\u00e9sicale en France: analyse quantitative des \u00e9v\u00e8nements ind\u00e9sirables graves notifi\u00e9s sur cinq ans","volume":"12","author":"Debois","year":"2002","journal-title":"Progr\u00e8s en Urol."},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0175","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.11.007","article-title":"Quinolone prophylaxis in conjunction with Bacillus Calmette-Gu\u00e9rin Instillations for bladder cancer: time to reconsider the evidence and open the quinolone box?","volume":"10","author":"Liedberg","year":"2024","journal-title":"Eur Urol Focus."},{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0180","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.euo.2024.12.013","article-title":"A Systematic review and meta-analysis of the clinical impact of prophylactic quinolones with adjuvant Bacillus Calmette-Gu\u00e9rin instillation for non-muscle-invasive bladder cancer","volume":"8","author":"Wong","year":"2025","journal-title":"Eur Urol Oncol."},{"issue":"7-8","key":"10.1016\/j.acuroe.2026.502005_bib0185","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.lpm.2012.10.017","article-title":"[Diagnosis and management of severe adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC)]","volume":"42","author":"Neuzillet","year":"2013","journal-title":"Presse Med."},{"issue":"6","key":"10.1016\/j.acuroe.2026.502005_bib0190","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","article-title":"Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study","volume":"8","author":"Numakura","year":"2022","journal-title":"Eur Urol Focus."},{"issue":"7","key":"10.1016\/j.acuroe.2026.502005_bib0195","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/cancers15071937","article-title":"Efficacy of Different Bacillus of Calmette-Gu\u00e9rin (BCG) Strains on Recurrence Rates among Intermediate\/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): single-arm study systematic review, cumulative and network meta-analysis","volume":"15","author":"Del Giudice","year":"2023","journal-title":"Cancers."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000492722","article-title":"Are there differences in toxicity and efficacy between various bacillus Calmette-Guerin strains in bladder cancer patients? Analysis of 844 patients","volume":"101","author":"Krajewski","year":"2018","journal-title":"Urol Int."},{"issue":"5","key":"10.1016\/j.acuroe.2026.502005_bib0205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/iju.13538","article-title":"Bacillus Calmette\u2013Gu\u00e9rin strain differences as the basis for immunotherapies against bladder cancer","volume":"25","author":"Miyazaki","year":"2018","journal-title":"Int J Urol."},{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.purol.2015.11.001","article-title":"Evaluation of adverse events caused by intravesical BCG instillations: has the strain used a potential implication?","volume":"26","author":"Holz","year":"2016","journal-title":"Prog en Urol."},{"issue":"9","key":"10.1016\/j.acuroe.2026.502005_bib0215","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.acuro.2017.03.003","article-title":"Adjuvant intravesical treatment for nonmuscle invasive bladder cancer: the importance of the strain and maintenance","volume":"41","author":"Guerrero-Ramos","year":"2017","journal-title":"Actas Urol Esp."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clgc.2019.10.021","article-title":"Comparative effectiveness of intravesical BCG-tice and BCG-moreau in patients with non-muscle-invasive bladder cancer","volume":"18","author":"D\u2019Andrea","year":"2020","journal-title":"Clin Genitourin Cancer."},{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0225","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40487-025-00334-6","article-title":"On the horizon: a global multidisciplinary perspective on delivering emerging therapies for patients with BCG-na\u00efve high-risk NMIBC","volume":"13","author":"Szabados","year":"2025","journal-title":"Oncol Ther."},{"issue":"5","key":"10.1016\/j.acuroe.2026.502005_bib0230","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/bjon.2024.0281","article-title":"A qualitative study exploring the experiences of nurses delivering bacillus Calmette-Gu\u00e9rin therapy","volume":"34","author":"F\u00f8rde","year":"2025","journal-title":"Br J Nurs."},{"issue":"6","key":"10.1016\/j.acuroe.2026.502005_bib0235","first-page":"332","article-title":"BCG y c\u00e1ncer de vejiga: pasado, presente y futuro","volume":"7","author":"Gonz\u00e1lez S\u00e1nchez","year":"2018","journal-title":"Arch Espa\u00f1oles Urol."},{"key":"10.1016\/j.acuroe.2026.502005_bib0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2020.10.039","article-title":"Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them","volume":"149","author":"Koch","year":"2021","journal-title":"Urology."},{"key":"10.1016\/j.acuroe.2026.502005_bib0245","series-title":"Intravesical instillation with mitomycin C or bacillus Calmette-Gu\u00e9rin in non-muscle invasive bladder cancer","first-page":"1","author":"Vahr","year":"2015"},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0250","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0022-5347(01)66224-4","article-title":"The quality of life during intravesical bacillus Calmette-Guerin therapy","volume":"155","author":"B\u00f6hle","year":"1996","journal-title":"J Urol."},{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0255","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0003-4401(01)00085-7","article-title":"Classification, favorable characteristics, prevention and treatment of adverse side-effects associated with Bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"36","author":"Saint","year":"2002","journal-title":"Ann Urol."},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0260","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0302-2838(03)00371-3","article-title":"The side effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 bladder Cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"Sylvester","year":"2003","journal-title":"Eur Urol."},{"issue":"9","key":"10.1016\/j.acuroe.2026.502005_bib0265","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Gu\u00e8rin therapy: experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"Andius","year":"2005","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0270","doi-asserted-by":"crossref","DOI":"10.1111\/ijun.70037","article-title":"Bladder Instillation Therapy Form (BITF)\u2014nursing instrument for intravesical Bacillus Calmette-Gu\u00e9rin instillations","volume":"19","author":"Danielsson","year":"2025","journal-title":"Int J Urol Nurs."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0275","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ijun.12236","article-title":"Withdrawing from treatment for bladder cancer: Patient experiences of BCG installations","volume":"14","author":"Alcorn","year":"2020","journal-title":"Int J Urol Nurs"},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0280","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1590\/S0365-05962011000400021","article-title":"Granulomas do p\u00eanis - uma complica\u00e7\u00e3o rara da terapia intravesical com bacilo calmette-gu\u00e9rin","volume":"86","author":"Lestre","year":"2011","journal-title":"An Bras Dermatol."},{"issue":"7","key":"10.1016\/j.acuroe.2026.502005_bib0285","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s11255-025-04375-8","article-title":"Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy","volume":"57","author":"Gubbiotti","year":"2025","journal-title":"Int Urol Nephrol."},{"issue":"7","key":"10.1016\/j.acuroe.2026.502005_bib0290","article-title":"Correction to: Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy","volume":"57","author":"Gubbiotti","year":"2025","journal-title":"Int Urol Nephrol."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12894-024-01675-6","article-title":"Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors: a systematic review and network meta-analysis","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Urol."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11934-024-01250-4","article-title":"Management of lower urinary tract symptoms during the treatment for non-muscle invasive bladder cancer","volume":"26","author":"Seiden","year":"2025","journal-title":"Curr Urol Rep."},{"issue":"21","key":"10.1016\/j.acuroe.2026.502005_bib0305","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1002\/cam4.4278","article-title":"Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors","volume":"10","author":"Sun","year":"2021","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0310","article-title":"Vibegron in overactive bladder: a comprehensive review of efficacy, safety and patient-reported outcomes","volume":"43","author":"Peyronnet","year":"2025","journal-title":"World J Urol."},{"key":"10.1016\/j.acuroe.2026.502005_bib0315","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2018.11.037","article-title":"Efficacy and safety of noninvasive intravesical instillation of onabotulinum Toxin-A for overactive bladder and interstitial cystitis\/bladder pain syndrome: systematic review and meta-analysis","volume":"125","author":"Lee","year":"2019","journal-title":"Urology."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0320","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose an","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol."},{"issue":"10","key":"10.1016\/j.acuroe.2026.502005_bib0325","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/imj.12876","article-title":"Systemic Bacillus Calmette-Guerin sepsis manifesting as hypercalcaemia and thrombocytopenia as a complication of intravesical Bacillus Calmette-Guerin therapy","volume":"45","author":"Nayar","year":"2015","journal-title":"Intern Med J."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0330","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bju.15870","article-title":"Clinical presentation of bacille Calmette-Gu\u00e9rin (BCG) infections after BCG instillation therapy","volume":"131","author":"Nurminen","year":"2023","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.acuroe.2026.502005_bib0335","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bju.15608","article-title":"Incidence of and mortality from Bacille Calmette-Gu\u00e9rin (BCG) infections after BCG instillation therapy","volume":"129","author":"Nurminen","year":"2022","journal-title":"BJU Int."},{"issue":"17","key":"10.1016\/j.acuroe.2026.502005_bib0340","first-page":"236","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical bcg administration as adjunctive therapy for bladder cancer incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"As\u00edn","year":"2014","journal-title":"Med (United States)."},{"issue":"6","key":"10.1016\/j.acuroe.2026.502005_bib0345","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11926-021-01004-y","article-title":"Reactive arthritis following bacillus calmette\u2013guerin therapy for bladder cancer: a systematic literature review","volume":"23","author":"Abdelghani","year":"2021","journal-title":"Curr Rheumatol Rep."},{"issue":"6","key":"10.1016\/j.acuroe.2026.502005_bib0350","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00296-005-0059-2","article-title":"Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review","volume":"26","author":"Tinazzi","year":"2006","journal-title":"Rheumatol Int."},{"issue":"6","key":"10.1016\/j.acuroe.2026.502005_bib0355","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms13061283","article-title":"Central nervous system infections caused by Bacillus Calmette-Guerin: case report and narrative literature review","volume":"13","author":"Chemello","year":"2025","journal-title":"Microorganisms."},{"issue":"2","key":"10.1016\/j.acuroe.2026.502005_bib0360","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10384-012-0120-0","article-title":"Bilateral orbital inflammation following intravesical bacille Calmette-Gu\u00e9rin immunotherapy for bladder cancer","volume":"56","author":"Takeuchi","year":"2012","journal-title":"Jpn J Ophthalmol."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0365","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.diagmicrobio.2012.05.026","article-title":"Miliary pulmonary tuberculosis following intravesical BCG therapy: case report and literature review","volume":"74","author":"Colmenero","year":"2012","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0370","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4103\/0255-0857.142254","article-title":"Disseminated Bacillus Calmette-Guerin infections after intravesical therapy","volume":"32","author":"Gerogianni","year":"2014","journal-title":"Indian J Med Microbiol."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0375","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s13104-017-2606-9","article-title":"Poncet\u2019s disease after the intravesical instillation of Bacillus Calmette-Gu\u00e9rin (BCG): A case report","volume":"10","author":"Sampaio","year":"2017","journal-title":"BMC Res Notes."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0380","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/mus.26328","article-title":"New onset of seropositive generalized myasthenia gravis following intravesical bacille Calmette-Guerin treatment for bladder cancer: a case study","volume":"59","author":"Davalos","year":"2019","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.acuroe.2026.502005_bib0385","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2026.502005_bib0390","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clinicoecon Outcomes Res."},{"key":"10.1016\/j.acuroe.2026.502005_bib0395","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clinicoecon Outcomes Res."},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/s1677-5538.ibju.2024.0615","article-title":"Multicenter Retrospective Registry Study on BCG Use in Non-Muscle Invasive Bladder Cancer in Latin America: BLATAM (Bladder Cancer in Latin America) Group","volume":"51","author":"Villoldo","year":"2025","journal-title":"Int Braz J Urol."},{"issue":"8","key":"10.1016\/j.acuroe.2026.502005_bib0405","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jjco\/hyt086","article-title":"Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer","volume":"43","author":"Miyazaki","year":"2013","journal-title":"Jpn J Clin Oncol."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0410","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000430501","article-title":"Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials?","volume":"96","author":"Serretta","year":"2016","journal-title":"Urol Int."},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0415","first-page":"290","article-title":"BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis","volume":"10","author":"Khene","year":"2024","journal-title":"Bl cancer"},{"key":"10.1016\/j.acuroe.2026.502005_bib0420","unstructured":"Tarjeta de informaci\u00f3n para el paciente Vejicur (BCG-Bacilo Calmette-Gu\u00e9rin) [Internet]. [access 21 de octubre de 2025]. Available from: http:\/\/www.aemps.gob.es\/vigilancia\/medicamentosUsoHumano\/docs\/."},{"key":"10.1016\/j.acuroe.2026.502005_bib0425","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-025-01921-2","article-title":"What do the current popular artificial intelligence chatbots offer us regarding patient information? Comparison of responses from the ten most popular chatbots about bladder cancer","author":"Sahin","year":"2025","journal-title":"J Cancer Surviv"},{"issue":"3","key":"10.1016\/j.acuroe.2026.502005_bib0430","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MOU.0000000000001267","article-title":"Artificial intelligence and patient education","volume":"35","author":"Paluszek","year":"2025","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0435","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.acuro.2021.12.002","article-title":"Optimizing treatment for non muscle-invasive bladder cancer with an app","volume":"46","author":"Beardo","year":"2022","journal-title":"Actas Urol Esp."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0440","first-page":"375","article-title":"A novel smartphone Application for bladder cancer management (BCM App): design, development, and usability evaluation","volume":"13","author":"Khosrobeigi","year":"2024","journal-title":"J Educ Health Promot."},{"issue":"4","key":"10.1016\/j.acuroe.2026.502005_bib0445","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.farma.2024.11.009","article-title":"Impacto de la atenci\u00f3n farmac\u00e9utica en la adherencia a los inhibidores de la tirosin-cinasa en la leucemia mieloide cr\u00f3nica","volume":"49","author":"Del Rosario Garc\u00eda","year":"2025","journal-title":"Farm Hosp."},{"issue":"5","key":"10.1016\/j.acuroe.2026.502005_bib0450","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/08971900251318574","article-title":"Early check-in protocol: identifying medication issues in patients with cancer at health system specialty pharmacy","volume":"38","author":"Phillips","year":"2025","journal-title":"J Pharm Pract."},{"issue":"1","key":"10.1016\/j.acuroe.2026.502005_bib0455","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm14010145","article-title":"Everolimus through plasmatic concentrations in cancer patients: prospective longitudinal observational multicentric study (DIANA-1 Project)","volume":"14","author":"Fort-Casamartina","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.acuroe.2026.502005_bib0460","series-title":"En: 13\u00b0 Tendiendo puentes Toledo","first-page":"P219","article-title":"Desarrollo y validaci\u00f3n de un m\u00e9todo anal\u00edtico para la monitorizaci\u00f3n simult\u00e1nea en plasma de abiraterona, imatinib, pazopanib y sunitinib: proyecto DIANA","author":"Gonzalo","year":"2025"},{"key":"10.1016\/j.acuroe.2026.502005_bib0465","series-title":"NIOSH list of hazardous drugs in healthcare settings, 2024","author":"Ovesen","year":"2024"},{"key":"10.1016\/j.acuroe.2026.502005_bib0470","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) treatment\u2019s severe complications: a single institution review of incidence, presentation and treatment outcome","volume":"19","author":"Waked","year":"2020","journal-title":"J Clin Tuberc other Mycobact Dis."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578626001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:31:55Z","timestamp":1792164715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578626001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2173578626001502"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.502005","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the prevention and treatment of adverse effects of intravesical BCG","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2026.502005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2026.502005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEU. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502005"}}